

Quarterly Progress Review

Q3 2024



Next-Generation injectable yttrium-90 therapy for solid cancer tumors.

VIVOS
PRECISION BRACHYTHERAPY

"If we can reach the tumor, we can kill it."

Precision Radionuclide Therapy™ (PRnT)

Executive Summary of Q3 2024

- The internal transformation of Vivos Inc into two operating divisions has been successfully implemented and is now a routine way of doing business.
- Each quarter we expand our trademark and patent protection in several countries based on our current technology and our development ideas for the future.

VIVOS

ISOPET® REVIEW

ANIMAL THERAPY DIVISION – ISOPET®

- We have successfully developed our technology and demonstrated its safety and effectiveness. Now we are focusing on opening more clinics and increasing the number of patients. We have redesigned our web presence, placed articles in key journals, attended several conferences, and are communicating on five social media platforms. LeeAnna Binder, our Marketing advisor is on a cross-country trip and is developing valuable contacts as a foundation for future growth.
- Based on a clear need we successfully treated our first exotic animal. Exotics include both pets and zoo animals.



RADIOGEL® REVIEW

HUMAN THERAPY DIVISION – RADIOGEL®

- Our most recent Investigational Device Exemption (IDE) submission addressed the previous FDA comments that they had raised over the last five years. The new review team had additional comments that we are currently addressing. We decided to withdraw our submission and deal with each category of remaining comments using the “sprint” process, which was available to us since our technology achieved Breakthrough Device designation.
- We have had five sprint meetings with the FDA with three more scheduled. We are using this feedback to strengthen our next IDE submission.



RADIOGEL® REVIEW

- We had been preparing for a detailed FDA audit of our manufacturing process by investing in a strong Quality Management System. The FDA comments reached into what we had assumed was future audit territory. As a result, we improved and are re-validating several procedures. We are confident that we will do well in any future FDA audit of our manufacturing process, which is required to initiate human therapy in the US.





CONFERENCES IN 2024

ACVIM (American College of Veterinary Internal Medicine) June 6-8, 2024 – Minneapolis, MN

PacVet (Pacific Veterinary Conference) – July 11-14, 2024 – San Francisco, CA

IRPA (International Radiation Protection Association) Darrell Fisher will be presenting “Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors” – July 7-12, 2024 – Orlando, FL

VCS (Cancer Society) – October 17-19 Orlando. FL

AAEP (Association of Equine Practitioners) – December 7 -11 – Orlando, FL

CONFERENCES IN 2025

VMX (the world’s premier veterinary expo) – Jan 25-29 – Orlando, FL

97th Annual WVS Conference (the largest and oldest veterinary conference in the USA) March 2-5 – Las Vegas, NV

ACVIM (American College of Veterinary Internal Medicine) – June 2-14 – Louisville, KY

VCS (Veterinary Cancer Society) – Sept 25-27 – Salt Lake City, UT